Avacincaptad pegol shows promising vision loss reduction rate in geographic atrophy
Click Here to Manage Email Alerts
A post hoc analysis of data from the GATHER1 and GATHER2 clinical trials showed that avacincaptad pegol achieved positive results in vision loss reduction in patients with geographic atrophy, according to a press release from Iveric Bio.
There was up to a 59% reduction in rate of vision loss with avacincaptad pegol (ACP) 2 mg compared with sham after 12 months of treatment.
Image: Adobe Stock.
GATHER1 had a 44% reduction in rate of vision loss, while GATHER2 had a 59% reduction. Together, the two clinical studies had a 56% reduction in rate of vision loss compared with sham in a combined analysis.
Further data will be presented at the Association for Research in Vision and Ophthalmology meeting in April.
“On average, it takes 2.5 years for GA lesions to start impacting central vision,” Arshad M. Khanani, MD, MA, FASRS, said in the release. “Early treatment effect has the potential to change the trajectory of disease for patients. A reduction in rate of vision loss with ACP 2 mg of up to 59% compared to sham treatment at 12 months supports the clinical relevance of the GATHER1 and GATHER2 primary endpoint, which met statistical significance.”
In February, the FDA granted priority review for a new drug application for ACP.
Read more about
Click Here to Manage Email Alerts